IGC Pharma (NYSE American: IGC) CEO Ram Mukunda provides an update on the company’s Phase 2 CALMA clinical trial for agitation in Alzheimer’s disease, announcing that enrollment has reached its target of 146 patients, with additional participants being enrolled to strengthen the study’s statistical analysis. He also discusses expanding trial sites, including Mount Sinai in New York, as the company moves toward completing dosing and preparing for topline results.
Mukunda also highlights IGC Pharma’s growing artificial intelligence initiatives, including MINT-AD, an AI model designed to help physicians identify patients at risk for Alzheimer’s disease, and a new agentic AI platform that harmonizes international Alzheimer’s datasets in collaboration with the Alzheimer’s Disease Data Initiative (ADDI). He explains why these technologies could improve early diagnosis, accelerate research, and support the future of Alzheimer’s care.
#IGCPharma
#IGC
#Alzheimers
#ArtificialIntelligence
#ClinicalTrials
#Dementia
#MINTAD
#HealthcareInnovation
#Biotechnology
#DrugDevelopment
#PrecisionMedicine
#MedicalResearch
#NYSEAmerican
#NewsOut
#ShotaBagaturia
source